Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.43 |
| ▸ | AKT2 | P31751 | 2/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22477777 | 0.84 | AKT1 (0.40) | AKT1AKT2AKT3KDM4EMAPT | |
| SCHEMBL21363576 | 0.78 | KDM4E (0.46) | KDM4ECYP1A2CYP2C19CDK9ALDH1A1 | |
| SCHEMBL19233674 | 0.77 | KDM4E (0.52) | AKT1AKT2AKT3KDM4EMAPT | |
| SCHEMBL17144457 | 0.76 | CYP1A2 (0.47) | AKT1AKT2AKT3KDM4EMAPT | |
| SCHEMBL26597001 | 0.74 | ATM (0.43) | AKT1AKT2AKT3ALOX5APKDM4E | |
| SCHEMBL25165855 | 0.73 | ALOX5AP (0.31) | ALOX5AP | |
| SCHEMBL12598270 | 0.73 | NOS2 (0.55) | KDM4ECYP1A2DYRK1AALDH1A1 | |
| SCHEMBL16084155 | 0.72 | CDK9 (0.42) | AKT1AKT2AKT3PRMT5CDK9 | |
| SCHEMBL21363710 | 0.72 | CYP1A2 (0.41) | AKT1AKT2AKT3KDM4EMAPT | |
| SCHEMBL1979492 | 0.72 | CYP1A2 (0.57) | AKT1KDM4EMAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | AKT1 2420/4885AKT2 3061/4885AKT3 2047/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | AKT1 2150/4885AKT2 2804/4885AKT3 1779/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | AKT1 2150/4885AKT2 2804/4885AKT3 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.